[{"id":"97e099ff-5286-4e2a-86a3-91ea5e73a0b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439085","created_at":"2021-01-29T07:16:58.643Z","updated_at":"2024-07-02T16:36:17.195Z","phase":"Phase 2","brief_title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","source_id_and_acronym":"NCT03439085","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • rocakinogene sifuplasmid (INO-9012) • INO-3112"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-14"},{"id":"fa08c05c-fc62-4ad7-b7eb-1a091aa3c5dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02172911","created_at":"2021-02-21T23:52:45.454Z","updated_at":"2024-07-02T16:36:34.313Z","phase":"Phase 1/2","brief_title":"A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer","source_id_and_acronym":"NCT02172911","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-3112"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/06/2014","start_date":" 06/06/2014","primary_txt":" Primary completion: 09/07/2017","primary_completion_date":" 09/07/2017","study_txt":" Completion: 09/07/2017","study_completion_date":" 09/07/2017","last_update_posted":"2021-02-21"},{"id":"9191d14a-5359-4697-90d1-ac86b9cf4e22","acronym":"","url":"https://clinicaltrials.gov/study/NCT02163057","created_at":"2021-01-18T10:04:15.979Z","updated_at":"2024-07-02T16:36:35.792Z","phase":"Phase 1/2","brief_title":"Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT02163057","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1","pipe":" | ","alterations":" TILs","tags":["CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-3112"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/13/2014","start_date":" 08/13/2014","primary_txt":" Primary completion: 01/23/2017","primary_completion_date":" 01/23/2017","study_txt":" Completion: 01/23/2017","study_completion_date":" 01/23/2017","last_update_posted":"2021-01-22"}]